"Pharmaceutical headline Jun" K drug combination therapy treatment liver cancer u.S. market rejected.

(2020/07/09) Large infusion leading alliance sitting in the 14 billion market "change"! Collum's 13 high-end imitations hit; why the century-old giant's share price rose 11 per cent after deciding to "abandon the machine"; and a batch of Chinese herbal medicines plunged dandelion, thymeOn July 8, Mercado and Aishi announced that the FDA had sent a complete response letter (CRL) to the two companies' applications for accelerated approval of Keytruda and Lenvima for first-line treatment in patients with non-removable hepatoblastoma's hopes of accelerating into the first-line therapy were dashednew type of coronavirus pneumonia is still spreading around the worldThe study shows that many patients with severe new coronavirus infection seisshow edillion characteristics such as IL-6, TNF-a, IFN-iso, indicating the possibility of mild or severe cytokine storms, which is an important cause of deathTherefore, the treatment of cytokine storms has become an important part of rescuing critical COVID-19 patientsLeukhemete interleukin-6 (IL-6) plays an important role in cytokine storms, and if it blocks the signal transduction pathway of IL-6, it is expected to be a new way to treat severely ill patientsthe future application prospects oftozhu-singtag are worth looking forward toJuly 8 query drug network found that, on a quarterly basis, the second quarter of a lot of Chinese herbal medicine significantly reduced prices, which is in sharp contrast to the first quarter of the sharp price increasesFor example, white flowers, prices fell by as much as 76.7 per cent, dandelions by as much as 68.8 per cent, and thyme, with prices down as much as 60 per centIn the future, Taodi medicinal herbs also have the potential to increase pricesSince July, the big infusion leading pharmaceutical companies continue to come to good news: Collum Pharmaceuticals has won Pfizer'
s global super$2 billion variety of acetic tablets of the domestic imitation; Domestic brand potential can be expectedpharmaceutical and biotech companies have been in the spotlight in the past few months, with dozens of companies around the world developing drugs and vaccines to fight neo-pneumonia, and in fact, the share prices of some pharmaceutical companies have doubled in just a few monthsHowever, not all pharmaceutical companies have a very valuable brand, and which pharmaceutical brands are on the list this year
Roche continues to growthis week, all over the country will gradually end the third batch of national organizations of centralized procurement of drug varieties of pre-harvest reporting workThis collection involves 52 varieties of 86 product regulations, including Capeta bin tablets, injection with aza cytosine, aunitrogen flat-mouth edifice and other large-selling varieties, the scale will be very largeAnd each collection of the original research manufacturers, is a testnational collection is a great opportunity, Olympus announced that it would transfer its digital camera and IC recorder-represented imaging business to Japan Industrial Partners AG (JIP), which plans to complete the transfer by the end of 2020, meaning Olympus has abandoned its 84-year-old imaging businessdeep-cultivated endoscope marketthe current outbreak, the development of clinical trials of new drugs, caused a considerable difficulty, such as the difficulty of patient recruitment, clinical process workload, as well as pharmaceutical companies research and development investmentBut even so, every new drug clinical trial is registered, but it still affects every nerve in the industryWhat about the first half of 2020 clinical trials of new drugs registered in China? What are the "golden-money" enterprises? What are the most popular areas of research and development?the innovation of domestic varieties still needs to be further strengthened.